News

News and Press Releases
Research | About the CF Foundation | Our Research Approach CF Foundation Awards Contract to Life Edit Therapeutics to Explore Gene Editing Technology in CF

Today, the Cystic Fibrosis Foundation announced that it has awarded up to $400,000 to Life Edit Therapeutics Inc. to explore the application of their unique gene editing technology in CF.

| 3 min read
Our Research Approach | Patient Registry | Research CF Foundation Launches Lung Transplant Biorepository and Patient Registry

The Cystic Fibrosis Lung Transplant Consortium Biorepository and Patient Registry, in collaboration with Cleveland Clinic, will provide critical clinical data and samples to support future research investigating complications of lung transplant.

| 4 min read
About the CF Foundation | Our Research Approach CF Foundation Launches New Collaboration to Overcome Challenges to Developing Genetic Therapies for CF

Today, the Cystic Fibrosis Foundation announced a collaboration with Deep Science Ventures to accelerate treatments that address the underlying cause of CF for every person with the disease. The collaboration will focus on uncovering and designing new technologies to address key scientific challenges on the Path to a Cure.

| 4 min read
Research | About the CF Foundation | Our Research Approach CF Foundation Funds Three New Research Awards to Advance its Path to a Cure Initiative

New funding awards include up to $2.6M to Eloxx Pharmaceuticals to identify potential therapies for CF nonsense mutations

| 5 min read
Research | About the CF Foundation | Our Research Approach CF Foundation Invests Up to $8.4M in SpliSense for the Development of Potential Rare Mutation Therapy

Today, the Cystic Fibrosis Foundation announced that it will invest up to $8.4 million in SpliSense's Series B funding round to develop an antisense oligonucleotide therapy for people with cystic fibrosis who have splicing mutations and potentially other rare mutations.

| 4 min read
Research | About the CF Foundation | Our Research Approach CF Foundation Awards Up to $2.17 Million to Beyond Air® to Develop Portable NTM Treatment

Today, the Cystic Fibrosis Foundation announced that it has awarded up to $2.17 million to Beyond Air® to support the development of a portable inhaled nitric oxide treatment for nontuberculous mycobacteria, difficult-to-treat bacteria that infect the lungs of people with cystic fibrosis.

| 4 min read
Research | About the CF Foundation | Our Research Approach CF Foundation Has Awarded Up to $3M to Kinnear Pharmaceuticals for Anti-Infective

The Cystic Fibrosis Foundation has awarded up to $3 million to Kinnear Pharmaceuticals to conduct preclinical testing of a broad-spectrum anti-infective that has the potential to treat multi-drug resistant Pseudomonas and other infections in people with cystic fibrosis.

| 3 min read